Table 5.
The MR of TAM and its metabolites between different combinations of CYP2D6 and CYP3A5 polymorphisms
| Combined phenotype | n (133) | TAM (ng/mL), p=0.265 | NDMT (ng/mL), p=0.114 | END (ng/mL), p=0.244 | 4OHT (ng/mL), p=0.224 |
|---|---|---|---|---|---|
| CYP2D6 (EM)–CYP3A5 (EM) | 31 | 373.13 (266.69) | 1,030.96 (487.88) | 72.86 (67.52) | 5.31 (2.76) |
| CYP2D6 (EM)–CYP3A5 (PM) | 24 | 365.23 (173.35) | 1,030.41 (738.27) | 58.71 (66.85) | 6.25 (2.80) |
| CYP2D6 (IM)–CYP3A5 (EM) | 51 | 358.31 (231.36) | 1,094.70 (630.68) | 46.56 (46.50) | 4.70 (2.62) |
| CYP2D6 (IM)–CYP3A5 (PM) | 25 | 425.63 (227.09) | 1,193.56 (610.65) | 57.47 (42.03) | 4.44 (3.22) |
| CYP2D6 (PM)–CYP3A5 (PM) | 2 | 238.36 (0.00) | 803.19 (0.00) | 41.86 (0.00) | 6.23 (0.00) |
|
| |||||
| Combined phenotype | n (133) | MR TAM-NDMT (p=0.032*) | MR NDMT-END (p=0.026*) | MR TAM-4OHT (p=0.079) | MR 4OHT-END (p=0.622) |
|
| |||||
| CYP2D6 (EM)–CYP3A5 (EM) | 31 | 0.38 (0.19) | 11.83 (7.06) | 65.09 (42.45) | 0.07 (0.08) |
| CYP2D6 (EM)–CYP3A5 (PM) | 24 | 0.34 (0.11) | 18.06 (27.87) | 60.29 (28.26) | 0.11 (0.17) |
| CYP2D6 (IM)–CYP3A5 (EM) | 51 | 0.34 (0.09) | 23.84 (27.62) | 75.47 (46.76) | 0.10 (0.14) |
| CYP2D6 (IM)–CYP3A5 (PM) | 25 | 0.35 (0.08) | 24.28 (17.3) | 78.98 (68.10) | 0.10 (0.07) |
| CYP2D6 (PM)–CYP3A5 (PM) | 2 | 0.30 (0.00) | 21.56 (0.00) | 40.48 (0.00) | 0.17 (0.00) |
Notes: The concentration of TAM and its metabolites are presented in median (interquartile range). p=p value from Kruskal–Wallis test,
*
p<0.05.
Abbreviations: 4OHT, 4-hydroxytamoxifen; EM, extensive metabolizer; END, endoxifen; IM, intermediate metabolizer; MR, metabolic ratios; NDMT, N-desmethyl tamoxifen; PM, poor metabolizer; TAM, tamoxifen.